Halozyme Therapeutics reported $47.76M in Stock for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Stock Change
Acadia Pharmaceuticals ACAD:US $ 7.01M 0.87M
Alnylam Pharmaceuticals ALNY:US $ 78.52M 44.18M
Amarin AMRN:US $ 267.82M 33.14M
Amgen AMGN:US $ 4411M 325M
Baxter International BAX:US $ 2548M 95M
Cara Therapeutics CARA:US 1.91M 677K
Esperion Therapeutics ESPR:US $ 35.65M 1.26M
Halozyme Therapeutics HALO:US $ 47.76M 6.15M
Intrexon XON:US $ 12.73M 0.53M
JAZZ PHA JAZZ:US $ 985.45M 87.27M
Nektar Therapeutics NKTR:US $ 15.8M 0.47M
Peregrine Pharmaceuticals PPHM:US $ 21.05M 0.74M
United Therapeutics UTHR:US $ 88.2M 5.6M
Vanda Pharmaceuticals VNDA:US 1.29M 265K